Arifoglu Hasan Basri, Duru Necati, Altunel Orhan, Baskan Burhan, Alabay Bedirhan, Atas Mustafa
Department of Ophthalmology, S.B. Kayseri Education and Research Hospital, Kayseri, Turkey.
Arq Bras Oftalmol. 2016 Jul-Aug;79(4):243-6. doi: 10.5935/0004-2749.20160069.
The objective of this study was to evaluate subfoveal choroidal thickness (SFCT) using enhanced depth imaging optical coherence tomography (EDI-OCT) in patients with naïve branch retinal vein occlusion (BRVO) before and after intravitreal dexamethasone implant (Ozurdex®) injection.
Thirty-nine patients with unilateral BRVO and 35 healthy subjects were included in this prospective study. Choroidal thickness was evaluated by EDI-OCT at baseline and 1 month after dexamethasone implant.
The mean SFCT measured in 39 patients with BRVO was 299.41 ± 55.86 µm, significantly greater than that in contralateral eyes (283.76 ± 57.44 µm; p=0.009) and control eyes (276.14 ± 39.06 µm; p=0.044). The mean SFCT after the treatment was 279.64 ± 50.96 µm, significantly thinner than that before intravitreal dexamethasone therapy (p=0.004).
SFCT in treatment-naive BRVO eyes was significantly greater than that in contralateral eyes and healthy eyes and decreased significantly after intravitreal dexamethasone implantation.
本研究的目的是使用增强深度成像光学相干断层扫描（EDI-OCT）评估初发视网膜分支静脉阻塞（BRVO）患者在玻璃体内注射地塞米松植入物（Ozurdex®）前后的黄斑下脉络膜厚度（SFCT）。
本前瞻性研究纳入了39例单侧BRVO患者和35名健康受试者。在基线和地塞米松植入后1个月通过EDI-OCT评估脉络膜厚度。
39例BRVO患者测量的平均SFCT为299.41±55.86μm，显著大于对侧眼（283.76±57.44μm；p = 0.009）和对照眼（276.14±39.06μm；p = 0.044）。治疗后的平均SFCT为279.64±50.96μm，显著薄于玻璃体内地塞米松治疗前（p = 0.004）。
初发BRVO眼的SFCT显著大于对侧眼和健康眼，并且在玻璃体内植入地塞米松后显著降低。
